XM does not provide services to residents of the United States of America.
P
P

Pfizer

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector

Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector COPENHAGEN, July 5 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO has been reprimanded by UK regulators for failing to disclose fees and expenses paid to individuals and organisations in Britain amounting to about 7.8 million pounds ($9.97 million) between 2020 and 2022. The UK industry body Prescription Medicines Code of Practice Authority (PMCPA) said on Friday that the reprimand followed a voluntary submi
N
P

Financial Times - July 3

PRESS DIGEST- Financial Times - July 3 July 3 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Hipgnosis founder Merck Mercuriadis to step down after Blackstone deal - UK port owners warn infrastructure improvement delays threaten renewables shift - Moderna secures partial victory in Covid vaccine legal fight - Water companies face legal challenges after landmark UK pollution ruling Ove
P

Pfizer defends appellate court’s ‘naming names’ rule in lawsuit over diversity program

Column: Pfizer defends appellate court’s ‘naming names’ rule in lawsuit over diversity program The opinions expressed here are those of the author, a columnist for Reuters. By Alison Frankel July 2 (Reuters) - Pfizer on Monday urged a U.S. appeals court not to revisit its decision to bar an anti-affirmative action group's challenge to the pharma company's diversity fellowship because the group failed to name people who had allegedly been harmed.
P

U.S. STOCKS Tesla, Archer Aviation, Novo Nordisk

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Archer Aviation, Novo Nordisk Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 edged up on Tuesday, boosted by gains in Tesla and megacap stocks, while the Dow was flat with investors assessing Federal Reserve Chairman Jerome Powell's comments on the need for more evidence before cutting rates.
I
P
P
P
P
T
L
O
W
U
U
U

US drugmakers fall as Biden urges price cuts on obesity drugs

BUZZ-US drugmakers fall as Biden urges price cuts on obesity drugs ** Shares of U.S. drugmakers down between 1% and 2% after President Joe Biden and Senator Bernie Sanders, in an opinion piece on USA Today, called out Eli Lilly LLY.N and Novo Nordisk NOVOb.CO to reduce high costs of their weight loss drugs ** They also pointed to high prices of all medicines across the United States compared to other nations ** U.S.
A
G
P
R

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.